The Great EU MedTech Squeeze: Portfolio Pruning and Consolidation Under MDR/IVDR in 2026

This episode examines the immense pressures facing medical device manufacturers from Europe's Medical Device Regulation (MDR) and In-Vitro Diagnostic Regulation (IVDR) leading up to 2026. We explore the two potential outcomes: widespread "portfolio pruning" and market consolidation due to high compliance costs and Notified Body bottlenecks, or the successful reduction of these pressures by regulators before essential devices are removed from the market. Key Questions: - What are the biggest challenges manufacturers face with the EU MDR and IVDR transition? - Why is the year 2026 so critical for the European MedTech market? - What is "portfolio pruning" and how could it affect patient care? - Will the shortage of Notified Bodies lead to a market crisis? - How are companies deciding which products to keep and which to discontinue? - Could MDR and IVDR compliance costs force smaller companies out of the market? - What steps can be taken to reduce the regulatory bottlenecks in Europe? - Is industry consolidation an inevitable outcome of these new regulations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies navigating complex landscapes like Europe's MDR/IVDR transition. We combine local expertise with advanced AI to streamline global market access, developing efficient regulatory strategies and compiling technical dossiers. Whether you are managing portfolio decisions or seeking new market entry, our team can help. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your global reach.